The results through 60 weeks of the PSUMMIT 2 trial, now published in Annals of the Rheumatic Diseases, reveal that patients with active psoriatic arthritis (PsA), including those previously treated ...

On December 1, 2024, Biocon announced that the FDA has approved YESINTEK™ (ustekinumab-kfce), a biosimilar to J&J’s STELARA®. YESINTEK is approved for the treatment of Crohn’s disease, Ulcerative ...

In an extension of a phase II clinical drug trial, ustekinumab (Stelara®) was found to be a safe and effective treatment for lupus over two years of use. Researchers assessed multiple measures of ...

Ustekinumab is a monoclonal antibody, prescribed for psoriasis. The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bacillus calmette-guerin substrain connaught ...

Janssen announced new data from the phase 3 UNIFI maintenance study (N=523) which evaluated ustekinumab subcutaneous (SC) maintenance therapy in adults with moderate to severe ulcerative colitis (UC).

The US Food and Drug Administration (FDA) has approved ustekinumab-auub (Wezlana) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. This is the first ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi® ...

Please provide your email address to receive an email when new articles are posted on . Abatacept treatment after ustekinumab withdrawal did not prevent psoriasis relapse, according to a randomized ...

Clinical response to ustekinumab for patients with psoriasis was shown to vary by body region, in which lower extremities were identified as the most difficult to treat. Lower response rates to ...

The monoclonal antibody ustekinumab (Stelara, Janssen Biotech Inc) induces response and remission in active moderate-to-severe Crohn's disease that is refractory to tumor necrosis factor (TNF) ...

SAN ANTONIO, Feb. 2 /PRNewswire/ -- One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically ...

The FDA has approved ustekinumab for the treatment of children aged 6 years and older with active psoriatic arthritis, according to a Janssen press release. “We know active pediatric psoriatic ...